Track topics on Twitter Track topics that are important to you
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to treat B-cell lymphomas; however, work conducted by Autolus has potentially opened a new therapeutic pathway for the treatment of T-cell lymphoma.
Therapies for T-cell lymphoma are notoriously difficult to develop because any treatment targeting T cells damages the body’s key line of defence against illness. On top of this, the T cell version of lymphoma is far more aggressive than the B-cell version, though more infrequently found.
Original Article: Promising new CAR-T therapy able to target T-cell lymphomaNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...